Incorporating the recent guidance downgrade
12/03/25 -"We have reduced our target price by c.11% (detail in the EPS section) but continue to foresee significant upside potential for Elekta. This optimism is underpinned by the strong demand for new ..."
Pages
69
Language
English
Published on
12/03/25
You may also be interested by these reports :
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...
07/05/25
Q2 figures exceeded expectations, surpassing consensus estimates (sales: +2.0%; adjusted EBIT: +4.4%). This was primarily due to pre-buying ...